Minocin
Total Payments
$36,042
Transactions
11
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $17,185 | 8 | 3 |
| 2022 | $58.92 | 2 | 2 |
| 2021 | $18,798 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $18,798 | 1 | 52.2% |
| Consulting Fee | $16,935 | 6 | 47.0% |
| Food and Beverage | $308.90 | 4 | 0.9% |
Payments by Type
Research
$18,798
1 transactions
General
$17,244
10 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Association between timing and choice of antimicrobial therapy for Stenotrophomonas maltophilia bloodstream infections in patients with hematologic malignancy | Melinta Therapeutics, LLC | $18,798 | 0 |
Top Doctors Receiving Payments for Minocin
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $18,798 | 1 |
| , M.D | Infectious Disease | Rancho Santa Fe, CA | $16,935 | 6 |
| Laura Means | Clinical Pharmacology | Lexington, KY | $124.99 | 1 |
| , PA-C | Physician Assistant | Houston, TX | $124.99 | 1 |
| , M.D | Critical Care Medicine | Brooklyn, NY | $40.88 | 1 |
| , MD, MPH | Internal Medicine | Boston, MA | $18.04 | 1 |
Ad
Manufacturing Companies
- Melinta Therapeutics, LLC $36,042
Product Information
- Type Drug
- Total Payments $36,042
- Total Doctors 5
- Transactions 11
About Minocin
Minocin is a drug associated with $36,042 in payments to 5 healthcare providers, recorded across 11 transactions in the CMS Open Payments database. The primary manufacturer is Melinta Therapeutics, LLC.
Payment data is available from 2021 to 2023. In 2023, $17,185 was paid across 8 transactions to 3 doctors.
The most common payment nature for Minocin is "Unspecified" ($18,798, 52.2% of total).
Minocin is associated with 1 research study, including "Association between timing and choice of antimicrobial therapy for Stenotrophomonas maltophilia bloodstream infections in patients with hematologic malignancy" ($18,798).